Poor
Mostly Misaligned
Patient Risk:
Medium
Summary
The AI response set includes multiple claims about food/Food-effect, GI side effects, and alcohol/HGPRT inhibition that are not supported or verifiable against the FDA label excerpts provided (which focus on malignancy/lymphoma risk). One malignancy-risk concept is supported by the provided boxed warning and related warnings.
Category Scores
Accurate Statements
Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans.
WARNING - MALIGNANCY: “Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans.”
Patients receiving immunosuppressants, including IMURAN, are at increased risk of developing lymphoma and other malignancies, particularly of the skin.
WARNINGS — Malignancy (Section 5): “Patients receiving immunosuppressants, including IMURAN, are at increased risk of developing lymphoma and other malignancies, particularly of the skin.”
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with IMURAN (with the majority occurring in Crohn's disease or ulcerative colitis).
WARNINGS — Malignancy (Section 5): “Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL)… have been reported in patients treated with IMURAN… [majority] occurred in patients with Crohn's disease or ulcerative colitis.”
Unsupported Statements
Azathioprine is a prodrug that requires metabolic conversion into its active form 6-mercaptopurine (6-MP).
Not supported by the provided label excerpts (which contain malignancy/lymphoma warning text only).
The oral bioavailability of azathioprine can be impacted by food consumption.
Not supported by the provided label excerpts.
Simultaneous administration of azathioprine with a meal results in higher concentrations of 6-MP compared to fasting.
Not supported by the provided label excerpts.
Taking azathioprine with food can increase its oral bioavailability and enhance its absorption.
Not supported by the provided label excerpts.
Azathioprine can cause gastrointestinal side effects such as nausea and vomiting.
Not supported by the provided label excerpts (no GI adverse reaction statements were included).
Healthcare providers may recommend taking azathioprine with a meal to alleviate discomfort.
Not supported by the provided label excerpts.
There isn't extensive research on the interaction between azathioprine and specific foods.
Not supported by the provided label excerpts.
Some studies suggest that the presence of certain nutrients may affect the metabolism of azathioprine.
Not supported by the provided label excerpts.
Alcohol consumption can decrease the conversion of azathioprine to 6-MP by inhibiting the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
Not supported by the provided label excerpts.
Contradictions
Important Omissions
No labeling details were provided regarding the asserted food-effects, alcohol/HGPRT mechanism, or GI side effects; these omissions prevent verification against the prescribing information for those specific claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Because several administration/interaction and adverse-effect claims were not supported by the provided label excerpts, the response may misrepresent important label-supported safety/administration information even though the malignancy warning content appears consistent with the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Most claims in the AI-generated list (food effect, GI side effects, provider recommendation, lack of research about food, nutrient effects, alcohol/HGPRT mechanism) are not supported by the FDA label excerpts provided (which only substantiate malignancy/lymphoma risk).
Suggested Improvement
Limit claims to sections supported by the provided label text (e.g., malignancy/lymphoma warnings). For food, alcohol, and GI tolerability statements, quote the exact relevant FDA label sections (Dosage/Administration, Warnings/Precautions, Drug Interactions, Adverse Reactions) to verify alignment.